ライフサイエンスコーパス: paraprotein

1 ression, associated with a decrease in serum paraprotein.

2 was positively correlated with the level of paraprotein.

3 ecreted by the tumor cells and the IgG serum paraprotein.

4 monoclonal antibodies, immune complexes and paraproteins.

5 c method to identify the cognate antigens of paraproteins.

6 rden of clonal plasma cells that produce the paraproteins.

7 s from all patients with HSP90-SUMO1-binding paraproteins.

8 s (1.9 years) than patients with IgA and IgG paraproteins (2.3 and 2.5 years, respectively) (P < .001

9 tinuum that requires the presence of a serum paraprotein and differs in severity of skin lesions, ext

10 We have prospectively evaluated serial paraprotein and serum free light chain (FLC) measurement

11 Serum paraproteins and/or light chains or bone marrow biopsy d

12 experienced a greater than 50% reduction in paraprotein, and four (17%) of 24 patients entered compl

13 of 18 cases, the serum contained benign IgM paraproteins, and in four of these cases at least two Ig

14 Plasma cells producing high levels of paraprotein are dependent on the unfolded protein respon

15 increase in FLC both alone and with a whole paraprotein, as a result of a significantly shorter surv

16 pathy, multifocal motor neuropathy, and some paraprotein-associated demyelinating neuropathies.

17 Paraprotein-associated neuropathies are a diverse group

18 Paraproteins can cause a remarkably diverse set of patho

19 relationship between SFLCR normalization and paraprotein clearance.

20 onic ataxic neuropathy, ophthalmoplegia, IgM paraprotein, cold agglutinins and disialosyl antibodies.

21 We found that paraproteins from a proportion of European, African-Amer

22 sumoylated and screened for reactivity with paraproteins from MGUS, MM, and WM patients.

23 E-MAP analysis of 2 MM paraproteins identified human cytomegalovirus (HCMV) as

24 ls in SCID-hu mice produced human monoclonal paraprotein (immunoglobulin M [IgM] and/or kappa or lamb

25 resulted in a greater than 25% reduction in paraprotein in 67% of patients, 13 patients (54%) experi

26 otein electrophoresis showed multiple clonal paraproteins in 4 of 5 cases.

27 chains (FLCs) are the most commonly detected paraproteins in chronic lymphocytic leukemia (CLL).

28 In three patients, all of whom had IgG-kappa paraproteins in their sera, the Abs were IgG-kappa.

29 in bands (APB), distinct from the presenting paraprotein, in 550 patients receiving high-dose therapy

30 physiology and the differential diagnosis of paraprotein-induced crystalline nephropathy.

31 was one complete response and a reduction in paraprotein levels and/or marrow plasmacytosis in eight

32 Reductions in the paraprotein levels were apparent within two months in 78

33 TGM1 cells, reduced serum myeloma-associated paraprotein levels, and better preservation of bone mine

34 th IgM AL amyloidosis have a significant IgM paraprotein (median, 10 g/L), less frequent lambda light

35 de in explaining the molecular mechanisms of paraprotein-mediated kidney injury.

36 Best responses of at least 25% reduction in paraprotein occurred in 17 (71%) of 24 patients (90% con

37 ented with a whole paraprotein relapsed with paraprotein only (PO) and "FLC escape," respectively.

38 ectrophoresis (IFE), could be due to altered paraprotein production by the malignant plasma cell clon

39 cytic infiltrate in bone marrow (BM) and IgM paraprotein production.

40 4 of 520 patients who presented with a whole paraprotein relapsed with paraprotein only (PO) and "FLC

41 lantation in the management of patients with paraprotein-related kidney disease continues to evolve.

42 We first reconstruct the paraprotein's epitope by analyzing the peptides that str

43 We observed inhibition of serum paraprotein secretion, inhibition of tumor growth, and i

44 SUMO1 carriers produced HSP90-SUMO1-specific paraproteins, suggesting that sumoylated HSP90 promotes

45 we identified a posttranslationally modified paraprotein target (paratargs) in monoclonal gammopathie

46 es reduced tumor load assessed by monoclonal paraprotein titers, prevented splenomegaly, limited deve

47 Protein and nucleotide sequencing of the paraproteins' variable regions revealed 2 predominant Vl

48 The median IgM paraprotein was 8 g/L and serum free light chain (FLC) r

49 An immunoglobulin M (IgM) kappa paraprotein was detected in 86%; the remainder had IgM l

50 Stable disease (less than 25% reduction in paraprotein) was observed in an additional 2 (8%) patien

51 and reduction in levels of circulating human paraprotein were observed in mice treated with B-B4-DM1.

52 The serum or urine levels of paraprotein were reduced by at least 90 percent in eight

53 and in four of these cases at least two IgM paraproteins were present.

54 vious efforts to reconstruct the epitopes of paraproteins, with the significant difference that it pr